105 related articles for article (PubMed ID: 11221880)
1. The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series.
Levine DA; Boyd J
Cancer Res; 2001 Feb; 61(3):908-11. PubMed ID: 11221880
[TBL] [Abstract][Full Text] [Related]
2. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
[TBL] [Abstract][Full Text] [Related]
3. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.
Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ
Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794
[TBL] [Abstract][Full Text] [Related]
4. Impact of androgen receptor cytosine-adenine-guanine polymorphisms on clinical outcome in BRCA mutation-associated epithelial ovarian cancers.
Li AJ; McAllister P; Karlan BY
Gynecol Oncol; 2010 Jan; 116(1):105-8. PubMed ID: 19818997
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype.
Dagan E; Friedman E; Paperna T; Carmi N; Gershoni-Baruch R
Eur J Hum Genet; 2002 Nov; 10(11):724-8. PubMed ID: 12404104
[TBL] [Abstract][Full Text] [Related]
6. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
7. Polymorphic CAG repeat length within the androgen receptor gene: identification of a subgroup of patients with increased risk of ovarian cancer.
Santarosa M; Bidoli E; Gallo A; Steffan A; Boiocchi M; Viel A
Oncol Rep; 2002; 9(3):639-44. PubMed ID: 11956643
[TBL] [Abstract][Full Text] [Related]
8. Risk of endometrial carcinoma associated with BRCA mutation.
Levine DA; Lin O; Barakat RR; Robson ME; McDermott D; Cohen L; Satagopan J; Offit K; Boyd J
Gynecol Oncol; 2001 Mar; 80(3):395-8. PubMed ID: 11263938
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
10. The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study.
Haiman CA; Brown M; Hankinson SE; Spiegelman D; Colditz GA; Willett WC; Kantoff PW; Hunter DJ
Cancer Res; 2002 Feb; 62(4):1045-9. PubMed ID: 11861380
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women.
Suter NM; Malone KE; Daling JR; Doody DR; Ostrander EA
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):127-35. PubMed ID: 12582022
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor gene CAG repeats, estrogen exposure status, and breast cancer susceptibility.
Wu MH; Chou YC; Yu CP; Yang T; You SL; Chen CJ; Sun CA
Eur J Cancer Prev; 2008 Aug; 17(4):317-22. PubMed ID: 18562955
[TBL] [Abstract][Full Text] [Related]
13. Androgen, progesterone, and FSH receptor polymorphisms in ovarian cancer risk and outcome.
Ludwig AH; Murawska M; Panek G; Timorek A; Kupryjanczyk J
Endocr Relat Cancer; 2009 Sep; 16(3):1005-16. PubMed ID: 19458022
[TBL] [Abstract][Full Text] [Related]
14. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.
Wang WW; Spurdle AB; Kolachana P; Bove B; Modan B; Ebbers SM; Suthers G; Tucker MA; Kaufman DJ; Doody MM; Tarone RE; Daly M; Levavi H; Pierce H; Chetrit A; Yechezkel GH; Chenevix-Trench G; Offit K; Godwin AK; Struewing JP
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):955-60. PubMed ID: 11535547
[TBL] [Abstract][Full Text] [Related]
15. Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study.
Hsing AW; Chokkalingam AP; Gao YT; Wu G; Wang X; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Chiang T; Chen YL; Stanczyk FZ; Chang C
Cancer Epidemiol Biomarkers Prev; 2002 Apr; 11(4):337-41. PubMed ID: 11927493
[TBL] [Abstract][Full Text] [Related]
16. CAG repeat length in exon 1 of the androgen receptor gene is related to age of diagnosis but not germ line BRCA1 mutation status in ovarian cancer.
Kim SC; Ju W; Mahavni V; Geisler JP; Buller RE
Int J Gynecol Cancer; 2006; 16 Suppl 1():190-4. PubMed ID: 16515589
[TBL] [Abstract][Full Text] [Related]
17. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
[TBL] [Abstract][Full Text] [Related]
18. Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology.
Li AJ; Elmore RG; Pavelka JC; Karlan BY
Gynecol Oncol; 2007 Dec; 107(3):420-3. PubMed ID: 17825390
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations.
Ramus SJ; Fishman A; Pharoah PD; Yarkoni S; Altaras M; Ponder BA
Eur J Surg Oncol; 2001 Apr; 27(3):278-81. PubMed ID: 11373105
[TBL] [Abstract][Full Text] [Related]
20. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis.
Paley PJ; Swisher EM; Garcia RL; Agoff SN; Greer BE; Peters KL; Goff BA
Gynecol Oncol; 2001 Feb; 80(2):176-80. PubMed ID: 11161856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
